<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803864</url>
  </required_header>
  <id_info>
    <org_study_id>SHDC2020CR2023B</org_study_id>
    <nct_id>NCT04803864</nct_id>
  </id_info>
  <brief_title>Study of Roxadustat in the Treatment of Acute Myocardial Infarction</brief_title>
  <acronym>ROXAMI</acronym>
  <official_title>A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Roxadustat in Patients With Acute ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depite successful primary percutaneous coronary intervention (PCI) and standardized medical&#xD;
      treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor,&#xD;
      with high morality and various complications such as heart failure. Roxadustat is a new drug&#xD;
      targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown&#xD;
      promising effect in reducing infarct size in pre-clinical studies.&#xD;
&#xD;
      This study aims to evaluate the efficacy and safety of early and short-term administration of&#xD;
      roxadustat in the treatment of acute ST-elevation myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, paralleled, randomized controlled trial. It aims to evaluate the&#xD;
      efficacy and safety of early and short-term administration of roxadustat in the treatment of&#xD;
      acute ST-elevation myocardial infarction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct Size</measure>
    <time_frame>30 days</time_frame>
    <description>Infarct size as a percentage of LV mass measured on delayed-enhanced CMR imaging 30 days post-MI compared to control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>0 - 1 year</time_frame>
    <description>Major adverse cardiovascular events (MACE) within 1 year follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Function</measure>
    <time_frame>1 month, 6 months, 1 year</time_frame>
    <description>Left ventricular end diastolic volume (LVEDV), Left ventricular end systolic volume (LVESV), Left ventricular ejection fraction (LVEF) changes during 1 year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes - peak concentration</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Peak Plasma Concentration (Cmax) of CK-MB, TnI and CK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes - Area under curve</measure>
    <time_frame>0 - 3 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of CK-MB, TnI and CK</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Myocardial fibrosis</measure>
    <time_frame>30 days</time_frame>
    <description>Fibroblast activation protein inhibitor (FAPI) tracer uptake in myocardium if selected patient underwent spontaneous PET/MR scan</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early and short-term Roxadustat treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients only receive conventional therapies as recommended by guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.</description>
    <arm_group_label>Roxadustat</arm_group_label>
    <other_name>Evrenzo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation&#xD;
&#xD;
          -  Coronary angiography within 12 hours of symptom onset, with TIMI flow grade 0 - 1 of&#xD;
             culprit vessel&#xD;
&#xD;
          -  Primary PCI with TIMI flow grade 2 - 3 after successful intervention&#xD;
&#xD;
          -  Capable and willing to provide informed consent and capable of completing study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous acute myocardial infarction history&#xD;
&#xD;
          -  Cardiogenic Shock at admission&#xD;
&#xD;
          -  Previously treated by roxadustat&#xD;
&#xD;
          -  Contraindications of roxadustat treatment&#xD;
&#xD;
          -  Contraindication of Cardiac MRI (e.g. eGFR &lt; 30 ml/min, pacemaker, metal prosthesis,&#xD;
             etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruiyan Zhang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuo Feng, M.D.</last_name>
    <phone>+86 15921388296</phone>
    <email>fengshuorv@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuo Feng, M.D.</last_name>
      <phone>+86 15921388296</phone>
      <email>fengshuorv@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoxiang Yan, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tianqi Zhu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Run Du, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuo Feng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Howell NJ, Tennant DA. The role of HIFs in ischemia-reperfusion injury. Hypoxia (Auckl). 2014 Jul 30;2:107-115. eCollection 2014. Review.</citation>
    <PMID>27774470</PMID>
  </reference>
  <reference>
    <citation>Sousa Fialho MDL, Abd Jamil AH, Stannard GA, Heather LC. Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease. Biochim Biophys Acta Mol Basis Dis. 2019 Apr 1;1865(4):831-843. doi: 10.1016/j.bbadis.2018.09.024. Epub 2018 Sep 25. Review.</citation>
    <PMID>30266651</PMID>
  </reference>
  <reference>
    <citation>Schreiber T, Salh√∂fer L, Quinting T, Fandrey J. Things get broken: the hypoxia-inducible factor prolyl hydroxylases in ischemic heart disease. Basic Res Cardiol. 2019 Mar 11;114(3):16. doi: 10.1007/s00395-019-0725-2. Review.</citation>
    <PMID>30859331</PMID>
  </reference>
  <reference>
    <citation>Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24.</citation>
    <PMID>31340089</PMID>
  </reference>
  <reference>
    <citation>Deguchi H, Ikeda M, Ide T, Tadokoro T, Ikeda S, Okabe K, Ishikita A, Saku K, Matsushima S, Tsutsui H. Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice. Circ J. 2020 May 25;84(6):1028-1033. doi: 10.1253/circj.CJ-19-1039. Epub 2020 Mar 24.</citation>
    <PMID>32213720</PMID>
  </reference>
  <reference>
    <citation>Groenendaal-van de Meent D, den Adel M, Rijnders S, Krebs-Brown A, Kerbusch V, Golor G, Schaddelee M. The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study. Clin Ther. 2016 Apr;38(4):918-28. doi: 10.1016/j.clinthera.2016.02.010. Epub 2016 Mar 4.</citation>
    <PMID>26947173</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>RUIYAN ZHANG</investigator_full_name>
    <investigator_title>Director of Cardiology Department, Chief Physician</investigator_title>
  </responsible_party>
  <keyword>ST Elevation Myocardial Infarction</keyword>
  <keyword>Roxadustat</keyword>
  <keyword>Infarct Size</keyword>
  <keyword>Cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data by contacting principle investigator of this study. Requests for IPD will be recieved, but this does not mean all requests will be shared by the investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>1 year after the end of this study</ipd_time_frame>
    <ipd_access_criteria>Please contact the investigators through email in the time frame.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

